

## Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

## SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection

Oct 14 2020, 8:30 AM EDT

## SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual Conference

Oct 12 2020, 8:30 AM EDT

## SCYNEXIS to Participate in H.C. Wainwright Conference and Maxim's Antifungal Webinar

Sep 10 2020, 8:38 AM EDT

## Stock Overview

Symbol	SCYX
Exchange	Nasdaq
Market Cap	53.01m
Last Price	\$5.00
52-Week	\$4.2009 - \$14.40

10/19/2020 04:00 PM EDT

## Investor Relations

LifeSci Advisors  
Irina Koffler  
T: 646-970-4681  
ikoffler@lifesciadvisors.com

## Leadership

### Marco Taglietti, M.D.

President and Chief Executive Officer

### David Angulo, M.D.

Chief Medical Officer

### Eric Francois

Chief Financial Officer

### Scott Sukenick

General Counsel

### Nkechi Azie, M.D., FIDSA

Vice President, Clinical Development and Medical Affairs

### Jim Maffezzoli

Vice President of Marketing and Sales

### Rajeshwar Motheram, Ph.D.

Vice President, Pharmaceutical Development

## SCYNEXIS, Inc.

1 Evertrust Plaza  
13th Floor  
Jersey City, NJ 07302

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.